← Back to Home

Eye Movement Changes After LRRK2 Degradation: Early Clues from Investigational Parkinson’s Drug ARV-102

In 24 patients treated for 28 days, a protein degradation strategy yielded exploratory signals in eye movements and cerebrospinal fluid markers. These changes help explain how the drug works, but key clinical tests remain before it can be shown to slow Parkinson’s disease.

By SURL BioNews

To alter the course of Parkinson’s disease, a new drug must clear two hurdles: enter the central nervous system and translate its molecular effects into benefits patients can experience. On October 7, Arvinas released final data from the Phase 1 trial of its oral drug candidate ARV-102, linking reductions in the target protein in cerebrospinal fluid with changes in eye movements and other biomarkers. However, the company also explicitly stated that this short-term trial was not designed to establish clinical efficacy.

ARV-102 uses PROTAC protein degradation technology to target LRRK2, a protein associated with Parkinson’s disease. It induces target breakdown through the cell’s existing protein disposal system, a mechanism distinct from that of inhibitors that block LRRK2 kinase activity. These data build on results announced earlier this year showing drug exposure in cerebrospinal fluid and reductions in LRRK2. The new focus is whether target reduction is accompanied by measurable changes in function and biological pathways.

According to conference data compiled by NeurologyLive, this single-center, double-blind trial was registered as EUCT 2024-516888-84-00. Participants were assigned in a 1:1:1:1 ratio to receive 20, 40, or 80 milligrams of ARV-102 daily, or placebo, for 28 days. The 24 participants who completed treatment had a median age of 62 years, and 83% were male. Enrolled patients did not have significant motor fluctuations or dyskinesia, so the applicability of the results is also limited by the characteristics of this group.

Eye movement testing used the Neuralight platform to assess insufficient movement amplitude when the eyes rapidly turn toward a target, known as “saccadic hypometria.” Arvinas said the treatment groups showed dose-dependent improvement compared with placebo; RTTNews also reported this company-announced result. This provides an objective window into motor control, but an improved ability to move the eyes toward a target does not yet allow a direct inference that walking, daily activities, or overall disability will also improve.

SomaScan protein analysis of cerebrospinal fluid offered another layer of clues. NeurologyLive reported decreases in CD68 and GPNMB, which are associated with endosomal–lysosomal function and neuroinflammation, and increases in NPTX2 and CBLN4, which are associated with synaptic and axonal biology. Percentage changes in LRRK2 also correlated with changes in CD68 and saccadic measures. These results make the connection between effects on the target and downstream responses more concrete, but correlation alone cannot prove that nerve cells have been protected or repaired.

Clinical motor scores also require careful interpretation. The mean changes in MDS-UPDRS Part III reported by NeurologyLive were an increase of 4.8 points in the placebo group and increases of 2.2, 1.6, and 0.8 points in the three treatment groups, respectively, in ascending dose order. These figures numerically favored ARV-102, but the confidence intervals for each group were wide and overlapped. This is not a result demonstrating improvement in motor symptoms. The small sample, treatment lasting only four weeks, and the exploratory nature of the eye movement and protein analyses all make these data more suitable for generating hypotheses for subsequent research.

### Background Context

Parkinson’s drug development is attempting to move from symptom relief toward disease modification, and ARV-102 offers one approach that intervenes through protein clearance. Arvinas believes these findings support continued clinical evaluation. The question that now needs to be answered is whether these early markers can be reproduced in larger, more diverse trials with longer follow-up, and whether they correspond to differences in patient function and disease progression. Molecular signals make the research direction clearer; efficacy still needs to be established through clinical outcomes.

References

  1. Arvinas via GlobeNewswire
  2. NeurologyLive
  3. RTTNews